Speech treatment improves dysarthria in multisystemic ataxia: a rater-blinded, controlled pilot-study in ARSACS

Redenlab partnered with investigators in Australia and Germany to conduct dysarthria treatment trial in ataxia published in Journal of Neurology

Abstract: We aimed to provide proof-of-principle evidence that intensive home-based speech treatment can improve dysarthria in complex multisystemic degenerative ataxias, exemplified by autosomal recessive spastic ataxia Charlevoix-Saguenay (ARSACS). Feasibility and piloting efficacy of speech training specifically tailored to cerebellar dysarthria was examined through a 4-week program in seven patients with rater-blinded assessment of intelligibility (primary outcome) and naturalness and acoustic measures of speech (secondary outcomes) performed 4 weeks before, immediately prior to, and directly after training (intraindividual control design). Speech intelligibility and naturalness improved post treatment. This provides piloting evidence that ataxia-tailored speech treatment might be effective in degenerative cerebellar disease.

See here for study details

Related Post

  • Posted on 17 June, 2024
    Up to half of all people with multiple sclerosis experience communication difficulties due to dysarthria, a disorder that impacts the...
    • Posted on 12 June, 2024
      Frontotemporal Dementia (FTD) encompasses a range of progressive neurodegenerative conditions that impair speech production and comprehension, higher cognitive functions, behavior,...
      • Posted on 7 June, 2024
        Redenlab’s CEO, Adam Vogel, co-wrote "The Role of Verbal Fluency in the Cerebellar Cognitive Affective Syndrome Scale in Friedreich Ataxia"...